Search results for "FUSION"

showing 10 items of 4513 documents

The VGVAPG Peptide Regulates the Production of Nitric Oxide Synthases and Reactive Oxygen Species in Mouse Astrocyte Cells In Vitro

2018

The products of elastin degradation, namely elastin-derived peptides (EDPs), are detectable in the cerebrospinal fluid of healthy individuals and in patients after ischemic stroke, and their number increases with age. Depending on their concentrations, both nitric oxide (NO) and reactive oxygen species (ROS) take part either in myocardial ischemia reperfusion injury or in neurovascular protection after ischemic stroke. The aim of our study was to determine the impact of VGVAPG peptide on ROS and NO production and expression of endothelial nitric oxide synthase (eNos), inducible nitric oxide synthase (iNos) and neuronal nitric oxide synthase (nNos) in mouse cortical astrocytes in vitro. Prim…

0301 basic medicineNitric Oxide Synthase Type IIINitric Oxide Synthase Type IInNosNitric Oxide Synthase Type INitric OxideBiochemistryNitric oxide03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundMice0302 clinical medicineEnosmedicineAnimalsReceptorchemistry.chemical_classificationGene knockdownReactive oxygen speciesOriginal PaperbiologyROSGeneral Medicinemedicine.diseasebiology.organism_classificationCell biologyElastin-derived peptidesNitric oxide synthaseiNos030104 developmental biologychemistryVGVAPGAstrocytesbiology.proteineNosFemaleNitric Oxide SynthasePeptidesReactive Oxygen SpeciesReperfusion injuryOligopeptides030217 neurology & neurosurgeryFetal bovine serumNeurochemical Research
researchProduct

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

2020

Background: Immune-checkpoint inhibitors have radically changed the treatment landscape of Non-Small-Cell Lung Cancer (NSCLC). It is still unclear whether specific clinical characteristics might identify those patients benefiting from immunotherapy more than others. The aim of this study was to identify clinical characteristics associated with disease-specific survival (DSS), time-to-treatment failure (TTF), objective responses (OR) and progressive disease (PD) in NSCLC patients treated with Nivolumab. Methods: This was a multicenter retrospective study conducted on 294 patients treated with Nivolumab for advanced NSCLC. Results: Of the more than 50 variables analyzed, five showed a signifi…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentClinical BiochemistryKaplan-Meier EstimateDisease-Free SurvivalDrug Administration ScheduleNO03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungDrug DiscoverymedicineMalignant pleural effusionHumansimmunotherapy; malignant pleural effusion; nivolumab; non-small-cell lung cancerIn patientmalignant pleural effusionLung cancerImmune Checkpoint InhibitorsRetrospective StudiesPharmacologynivolumabbusiness.industryBrain NeoplasmsLiver NeoplasmsImmunotherapymedicine.diseasePrognosisPleural Effusion Malignantrespiratory tract diseases030104 developmental biologyTreatment Outcomenon-small-cell lung cancer030220 oncology & carcinogenesisFemalesense organsNon small cellimmunotherapyNivolumabbusiness
researchProduct

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

2016

Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagnosed multiple myeloma.In this phase 3 trial, we randomly assigned 498 patients with relapsed or relapsed and refractory multiple myeloma to receive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (control group) or in combination with daratumumab (16 mg per kilogram of body weight) (daratumumab group). The primary end point was progression-free survival.A prespecifie…

0301 basic medicineOncologyMaleAntigens CD38Drug ResistanceDexamethasoneIxazomibBortezomibchemistry.chemical_compound0302 clinical medicineRecurrenceMonoclonalAntineoplastic Combined Chemotherapy ProtocolsMedicineInfusions IntravenouElotuzumabInfusions IntravenousMultiple myelomaIsatuximabBortezomibMedicine (all)SLAMF7Antibodies MonoclonalGeneral MedicineMiddle Aged030220 oncology & carcinogenesisFemaleIntravenousMultiple MyelomaHumanmedicine.drugAdult; Aged; Antibodies Monoclonal; Antigens CD38; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Resistance Neoplasm; Female; Humans; Infusions Intravenous; Male; Middle Aged; Multiple Myeloma; Recurrence; Medicine (all)AdultInfusionsmedicine.medical_specialtyAntibodiesDisease-Free Survival03 medical and health sciencesInternal medicineHumansAntigensAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industryDaratumumabInterim analysismedicine.diseaseADP-ribosyl Cyclase 1Surgery030104 developmental biologychemistryDrug Resistance NeoplasmNeoplasmbusinessCD38The New England journal of medicine
researchProduct

Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After All…

2020

Currently, the prognosis of Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients relapsing after an allogenic hematopoietic stem cell transplantation (allo-SCT) remains poor, with few therapeutic options available. Here we present the case of a 32 years old patient with dasatinib-resistant post-transplant molecular relapse of ALL, who received, as second-line therapy, the combination of ponatinib and donor lymphocyte infusion (DLI). The therapy was safe and the patient achieved a sustained minimal residual disease negative disease, still ongoing after 22 months, which was accompanied by several changes in the immune populations distribution within the bone marrow (i.e., the increase in the C…

0301 basic medicineOncologymedicine.medical_specialtyCancer Researchmedicine.medical_treatmentT lymphocytesCase ReportHematopoietic stem cell transplantationlcsh:RC254-282Donor lymphocyte infusionbone marrow microenviroment03 medical and health scienceschemistry.chemical_compound0302 clinical medicineacute lymhoblastic leukemiaInternal medicinehemic and lymphatic diseasesT lymphocytemedicineponatinibbusiness.industryPonatinibDonor Lymphocyteslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensDasatinib030104 developmental biologymedicine.anatomical_structurechemistryOncology030220 oncology & carcinogenesisdonor lymphocyte infusion (DLI)Bone marrowStem cellbusinessCD8medicine.drugFrontiers in Oncology
researchProduct

2020

Orthodontic tooth movement to therapeutically align malpositioned teeth is supposed to impact blood flow in the surrounding tissues. Here, we evaluated actual vascularization in the tension area of the periodontal ligament during experimental tooth movement in rats (N = 8) with magnetic resonance imaging (MRI). We inserted an elastic band between the left upper first and the second rat molar; the right side was not treated and served as control. After four days of tooth movement, we recorded T1-weighted morphologic and dynamic-contrast-enhanced MRI sequences with an animal-specific 7 Tesla MRI to assess of local vascularization. Furthermore, we quantified osteoclasts and monocytes in the pe…

0301 basic medicineOrthodonticsMolarmedicine.diagnostic_testbusiness.industryRat modelMedicine (miscellaneous)Magnetic resonance imaging030206 dentistryBlood flowGeneral Biochemistry Genetics and Molecular Biologystomatognathic diseases03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structurestomatognathic systemOsteoclastTooth movementmedicinePeriodontal fiberbusinessPerfusionBiomedicines
researchProduct

Alterations in White Matter Network and Microstructural Integrity Differentiate Parkinson’s Disease Patients and Healthy Subjects

2019

Parkinson’s disease (PD) is a neurodegenerative disease, neuropathologically characterized by progressive loss of neurons in distinct brain areas. We hypothesize that quantifiable network alterations are caused by neurodegeneration. The primary motivation of this study was to assess the specific network alterations in PD patients that are distinct but appear in conjunction with physiological aging. 178 subjects (130 females) stratified into PD patients, young, middle-aged and elderly healthy controls (age- and sex-matched with PD patients), were analyzed using 3D-T1 magnetization-prepared rapid gradient-echo (MPRAGE) and diffusion weighted images acquired in 3T MRI scanner. Diffusion modeli…

0301 basic medicineParkinson's diseaseCognitive NeuroscienceSpleniumCorpus callosumcomputer.software_genrelcsh:RC321-571White matterdiffusion MRI03 medical and health sciences0302 clinical medicineVoxelMedicinelcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchbusiness.industryagingmedicine.diseasenetwork connectivity analysis030104 developmental biologymedicine.anatomical_structureCorticospinal tractParkinson’s diseasebusinessNeuroscienceInsulacomputerwhite matter030217 neurology & neurosurgeryNeuroscienceDiffusion MRIFrontiers in Aging Neuroscience
researchProduct

Gene Expression (mRNA) Markers for Differentiating between Malignant and Benign Follicular Thyroid Tumours

2017

Distinguishing between follicular thyroid cancer (FTC) and follicular thyroid adenoma (FTA) constitutes a long-standing diagnostic problem resulting in equivocal histopathological diagnoses. There is therefore a need for additional molecular markers. To identify molecular differences between FTC and FTA, we analyzed the gene expression microarray data of 52 follicular neoplasms. We also performed a meta-analysis involving 14 studies employing high throughput methods (365 follicular neoplasms analyzed). Based on these two analyses, we selected 18 genes differentially expressed between FTA and FTC. We validated them by quantitative real-time polymerase chain reaction (qRT-PCR) in an independe…

0301 basic medicinePathologyMicroarrayThyroid Glandlaw.inventionlawFollicular phaseGene expressionAdenocarcinoma Follicularfollicular thyroid adenoma; follicular thyroid cancer; gene expression; microarray; meta-analysisSpectroscopyPolymerase chain reactionOligonucleotide Array Sequence Analysisfollicular thyroid cancerGeneral MedicineCANCERComputer Science ApplicationsGene Expression Regulation NeoplasticCARCINOMASFUSION ONCOGENEmicroarrayNEOPLASMSmedicine.medical_specialtyMOLECULAR MARKERSASPIRATIONBiologyCatalysisCLASSIFICATIONArticleInorganic Chemistry03 medical and health sciencesNODULESADENOMASmedicineBiomarkers TumorHumansRNA MessengerThyroid NeoplasmsPhysical and Theoretical ChemistryFollicular thyroid cancerMolecular BiologyGeneGene Expression ProfilingOrganic ChemistryThyroid adenomaACVRL1medicine.diseaseMODELmeta-analysis030104 developmental biologyfollicular thyroid adenomaMutationgene expressionInternational Journal of Molecular Sciences
researchProduct

A longitudinal DTI and histological study of the spinal cord reveals early pathological alterations in G93A-SOD1 mouse model of amyotrophic lateral s…

2017

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by selective motor neuron degeneration in the motor cortex, brainstem and spinal cord. It is generally accepted that ALS is caused by death of motor neurons, however the exact temporal cascade of degenerative processes is not yet completely known. To identify the early pathological changes in spinal cord of G93A-SOD1 AIS mice we performed a comprehensive longitudinal analysis employing diffusion-tensor magnetic resonance imaging alongside histology and electron microscopy, in parallel with peripheral nerve histology. We showed the gradient of degeneration appearance in spinal cord white and gray matter, startin…

0301 basic medicinePathologyNeurologyTime FactorsMotor neuron diseasesSensory Receptor CellMice0302 clinical medicineImage Processing Computer-AssistedAxonAmyotrophic lateral sclerosisGray MatterAnthracenesWhite MatterMitochondriamedicine.anatomical_structureDiffusion Tensor ImagingNeurologySpinal CordG93A-SOD1 miceBrainstemHumanMotor cortexmedicine.medical_specialtyAxon degenerationTime FactorSensory Receptor CellsSOD1Mice TransgenicWhite matter03 medical and health sciencesMagnetic resonance imagingDevelopmental NeuroscienceMicroscopy Electron TransmissionmedicineElectron microscopyAnimalsHumansMotor neuron diseaseAmyotrophic lateral sclerosiAnimalbusiness.industrySuperoxide DismutaseAmyotrophic Lateral SclerosisSpinal cordmedicine.diseaseAmyotrophic lateral sclerosisMice Inbred C57BLDisease Models Animal030104 developmental biologyAnthracenebusinessNeuroscience030217 neurology & neurosurgeryExperimental neurology
researchProduct

The Impacts of Tumor and Tumor Associated Epilepsy on Subcortical Brain Structures and Long Distance Connectivity in Patients With Low Grade Glioma

2018

Low grade gliomas in cerebral cortex often cause symptoms related to higher cerebral functions such as attention, memory and executive function before treatment is initiated. Interestingly, focal tumors residing in one cortical region can lead to a diverse range of symptoms, indicating that the impact of a tumor is extended to multiple brain regions. We hypothesize that the presence of focal glioma in the cerebral cortex leads to alterations of distant subcortical areas and essential white matter tracts. In this study, we analyzed diffusion tensor imaging scans in glioma patients to study the effect of glioma on subcortical gray matter nuclei and long-distance connectivity. We found that th…

0301 basic medicinePathologymedicine.medical_specialtyBrain tumorlcsh:RC346-429White matter03 medical and health sciences0302 clinical medicinegliomaGliomamedicinelcsh:Neurology. Diseases of the nervous systemOriginal Researchtumor associated epilepsybusiness.industrydiffusion tensor imagingmedicine.diseaseSubcortical gray matter030104 developmental biologymedicine.anatomical_structureNeurologyCerebral cortexconnectivityCerebellar cortexNeurology (clinical)business030217 neurology & neurosurgeryMRIDiffusion MRITractography
researchProduct

Immunohistochemical analysis of NKX2.2, ETV4, and BCOR in a large series of genetically confirmed Ewing sarcoma family of tumors

2017

Ewing sarcoma is an aggressive neoplasm of pediatric and adolescent patients. Immunohistochemistry (IHC) can be used to support the morphologic diagnosis of Ewing sarcoma family of tumors (ESFT) in a convincing clinical/radiological context. Although neither NKX2.2 nor CD99 alone are entirely specific, when combined, the diagnostic specificity is high. The aim of the present study was to investigate the IHC expression of NKX2.2, ETV4 and BCOR in a large series of genetically confirmed ESFT. The results for CD99 and CAV-1 immunoreactivity, and the histological and fusion gene subtypes were retrieved from our previous study. NKX2.2 demonstrated moderate or strong nuclear positivity in 91.2% o…

0301 basic medicinePathologymedicine.medical_specialtyCD99Bone NeoplasmsContext (language use)Sarcoma EwingBiologyPathology and Forensic MedicineFusion gene03 medical and health sciences0302 clinical medicineProto-Oncogene ProteinsBiomarkers TumormedicineHumansNeoplasmHomeodomain ProteinsProto-Oncogene Proteins c-etsNuclear ProteinsCell BiologyZebrafish Proteinsmedicine.diseaseImmunohistochemistryRepressor ProteinsHomeobox Protein Nkx-2.2030104 developmental biology030220 oncology & carcinogenesisCancer researchbiology.proteinImmunohistochemistryAdenovirus E1A ProteinsSarcomaMorphologic diagnosisAntibodyTranscription FactorsPathology - Research and Practice
researchProduct